» Articles » PMID: 33706076

Novel PROTACs for Degradation of SHP2 Protein

Overview
Journal Bioorg Chem
Publisher Elsevier
Specialties Biochemistry
Chemistry
Date 2021 Mar 11
PMID 33706076
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Protein tyrosine phosphatase SHP2 is a member of PTPs family associated with cancer such as leukemia, non-small cell lung cancer, breast cancer, and so on. SHP2 is a promising target for drug development, and consequently it is of great significance to develop SHP2 inhibitors. Herein, we report CRBN-recruiting PROTAC molecules targeting SHP2 by connecting pomalidomide with SHP099, an allosteric inhibitor of SHP2. Among them, SP4 significantly inhibited the growth of Hela cells, compared with SHP099, its activity increased 100 times. In addition, it can significantly induce SHP2 degradation and cell apoptosis. Further study of SHP2-protac may have important significance for the treatment of SHP2 related diseases.

Citing Articles

Application of PROTACs in Target Identification and Target Validation.

Liu Y, Liang J, Zhu R, Yang Y, Wang Y, Wei W Acta Mater Med. 2024; 3(1):72-87.

PMID: 39373008 PMC: 11452161. DOI: 10.15212/amm-2024-0010.


Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes.

Taylor J, Barrett N, Martinez Cuesta S, Cassidy K, Pachl F, Dodgson J Commun Biol. 2024; 7(1):1179.

PMID: 39300128 PMC: 11415077. DOI: 10.1038/s42003-024-06803-4.


Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.

Tang K, Wang S, Feng S, Yang X, Guo Y, Ren X Acta Pharm Sin B. 2024; 14(8):3624-3642.

PMID: 39234614 PMC: 11372460. DOI: 10.1016/j.apsb.2024.03.028.


Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases.

Wang A, Zhang Y, Lv X, Liang G Acta Pharm Sin B. 2024; 14(8):3295-3311.

PMID: 39220870 PMC: 11365412. DOI: 10.1016/j.apsb.2024.05.006.


Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.

Kamaraj R, Ghosh S, Das S, Sen S, Kumar P, Majumdar M Bioconjug Chem. 2024; 35(8):1089-1115.

PMID: 38990186 PMC: 11342303. DOI: 10.1021/acs.bioconjchem.4c00253.